Pioglitazone modulates vascular inflammation in atherosclerotic rabbits: Noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging

JACC: Cardiovascular Imaging

Volumn 4, Issue 10, 2011, Pages 1100-1109

  Vucic, Esad ^a,f   Dickson, Stephen D ^a   Calcagno, Claudia ^a   Rudd, James H F ^b   Moshier, Erin ^a   Hayashi, Katsumi ^a   Mounessa, Jessica S ^a   Roytman, Michelle ^a   Moon, Matthew J ^a   Lin, James ^a   Tsimikas, Sotirios ^c   Fisher, Edward A ^d   Nicolay, Klaas ^e   Fuster, Valentin ^f,g   Fayad, Zahi A ^a,f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^f MOUNT SINAI HOSPITAL   (United States)

^g CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

18F fluorodeoxyglucose positron emission tomography computed tomography; atherosclerosis; dynamic contrast enhanced magnetic resonance imaging; inflammation; pioglitazone

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PHOSPHOLIPID; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; AREA UNDER THE CURVE; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIAC IMAGING; CELL DENSITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; HYPERLIPIDEMIA; IMMUNOHISTOLOGY; IMMUNOREACTIVITY; MACROPHAGE; METABOLIC PARAMETERS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SERUM; VASCULITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA; AORTOGRAPHY; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FLUORODEOXYGLUCOSE F18; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIPIDS; MACROPHAGES; MAGNETIC RESONANCE ANGIOGRAPHY; NEOVASCULARIZATION, PATHOLOGIC; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PPAR GAMMA; PREDICTIVE VALUE OF TESTS; RABBITS; RADIOPHARMACEUTICALS; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 80054091294     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2011.04.020     Document Type: Article

References (28)

1. B. Dahlöf Cardiovascular disease risk factors: epidemiology and risk assessment Am J Cardiol 105 2010 3A 9A
2. P. Libby, P.M. Ridker, and G.K. Hansson Inflammation in atherosclerosis: from pathophysiology to practice J Am Coll Cardiol 54 2009 2129 2138
3. R. Ross Atherosclerosisan inflammatory disease N Engl J Med 340 1999 115 126
4. V. Fuster, P.R. Moreno, Z.A. Fayad, R. Corti, and J.J. Badimon Atherothrombosis and high-risk plaque: part I Evolving concepts J Am Coll Cardiol 46 2005 937 954 (Pubitemid 41316498)
5. P. Natarajan, K.K. Ray, and C.P. Cannon High-density lipoprotein and coronary heart disease: current and future therapies J Am Coll Cardiol 55 2010 1283 1299
6. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211 (Pubitemid 351754991)
7. N. Marx, F. Mach, and A. Sauty Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells J Immunol 164 2000 6503 6508 (Pubitemid 30408835)
8. Y. Takata, Y. Kitami, Z.-H. Yang, M. Nakamura, T. Okura, and K. Hiwada Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-δ and peroxisome proliferator-activated receptor-γ Circ Res 91 2002 427 433 (Pubitemid 35034211)
9. A.R. Collins, W.P. Meehan, and U. Kintscher Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice Arterioscler Thromb Vasc Biol 21 2001 365 371 (Pubitemid 32199117)
10. A.C. Li, K.K. Brown, M.J. Silvestre, T.M. Willson, W. Palinski, and C.K. Glass Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice J Clin Invest 106 2000 523 531 (Pubitemid 30666385)
11. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med;170:1191201.
12. J.A. Dormandy, B. Charbonnel, and D.J.A. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
13. J.H. Rudd, F. Hyafil, and Z.A. Fayad Inflammation imaging in atherosclerosis Arterioscler Thromb Vasc Biol 29 2009 1009 1016
14. K. Chang, S.A. Francis, and E. Aikawa Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging Arterioscler Thromb Vasc Biol 30 2010 1933 1939
15. 18F- fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients J Am Coll Cardiol 48 2006 1818 1824 (Pubitemid 44648622)
16. J.H.F. Rudd, E.A. Warburton, and T.D. Fryer Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography Circulation 105 2002 2708 2711 (Pubitemid 34615139)
17. C. Calcagno, J.C. Cornily, and F. Hyafil Detection of neovessels in atherosclerotic plaques of rabbits using dynamic contrast enhanced MRI and 18F-FDG PET Arterioscler Thromb Vasc Biol 28 2008 1311 1317
18. J.H. Rudd, K.S. Myers, and S. Bansilal Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study Circ Cardiovasc Imaging 2 2009 107 115
19. 18F-FDG PET/CT and histology J Nucl Med 50 2009 959 965
20. M. Joner, A. Farb, and Q. Cheng Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-{beta} and MCP-1 Arterioscler Thromb Vasc Biol 27 2007 182 189 (Pubitemid 46360397)
21. J.P. McVicar, S.T. Kunitake, R.L. Hamilton, and J.P. Kane Characteristics of human lipoproteins isolated by selected-affinity immunosorption of apolipoprotein A-I Proc Natl Acad Sci U S A 81 1984 1356 1360 (Pubitemid 14173468)
22. C. Littell Ramon, G.A. Miliken, W.W. Stroup, and R.D. Wolfinger SAS System for Mixed Models 1996 SAS Institute Inc Cary, NC
23. W.W. Stroup Mixed model procedures to assess power, precision, and sample size in the design of experiments Proc Biopharmaceutical Section Am Stat Assoc 1999 15 24
24. A. Tawakol, R.Q. Migrino, and U. Hoffmann Noninvasive in vivo measurement of vascular inflammation with F-18 fluorodeoxyglucose positron emission tomography J Nucl Cardiol 12 2005 294 301 (Pubitemid 40790404)
25. N. Tahara, H. Kai, and M. Ishibashi Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography J Am Coll Cardiol 48 2006 1825 1831 (Pubitemid 44648621)
26. 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques J Nucl Med 47 2006 1845 1850 (Pubitemid 47545007)
27. M.E. Lobatto, Z.A. Fayad, and S. Silvera Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis Mol Pharm 7 2010 2020 2029
28. HRP initiative. http://www.hrpinitiative.com Accessed August 22, 2011